Fish Growth Hormone ELISA Kit

Name: Fish Growth Hormone ELISA Kit
SKU: DEIASL126
Rating: 5 (1 reviews)

Regulatory status: For research use only, not for use in diagnostic procedures.

COA

SDS

Datasheet

Summary

Sample

Cell culture supernate, serum and plasma

Species Reactivity

Fish

Detection Method

cELISA

Intended Use

This ELISA kit used for quantitation of Zebra Fish Growth Hormone (GH) concentration in cell culture supernate, serum and plasma. It can be also used for common carp, grass carp and some other fishes.

Contents of Kit

1. Assay plate 1(96 wells)
2. Standard 6 × 1 mL S0-S5, 0, 312.5, 625, 1250, 2500 and 5000 pg/mL
3. Conjugate 1 × 6 mL
4. HRP-avidin 1 × 6 mL
5. Wash Buffer (20 × concentrate) 1 × 15 mL
6. Substrate A 1 × 7 mL
7. Substrate B 1 × 7 mL
8. Stop Solution 1 × 7 mL
9. Adhesive Strip (For 96 wells) 4
10. Instruction manual 1

Storage

The kit should to be stored in the refrigerator (2–8°C).

Precision

Intra-assay Precision (Precision within an assay): CV% < 15%
Three samples of known concentration were tested twenty times on one plate to assess.
Inter-assay Precision (Precision between assays): CV% < 15%
Three samples of known concentration were tested in twenty assays to assess.

Detection Range

312.5 pg/mL - 5000 pg/mL

Sensitivity

The minimum detectable dose of fish GH is typically less than 312.5 pg/mL. The sensitivity of this assay, or Lower Limit of Detection (LLD) was defined as the lowest fish GH concentration that could be differentiated from zero.

General Notes

Hormone Markers ELISA Kits

Citations

Have you cited DEIASL126 in a publication? Let us know and earn a reward for your research.

Background

The anterior pituitary of fish secretes Fish Growth Hormone (FGH), a significant hormone that is categorized as a protein hormone. By mainly activating particular signaling pathways to support growth, muscular, and skeletal development, FGH plays a critical role in controlling growth, development, and metabolism in fish. It also somewhat affects immunological function and reproductive maturation. Fish growth rate and farming efficiency can be improved by FGH, making it a valuable use in aquaculture. FGH shares structural similarities with mammalian growth hormones. It is a peptide hormone with a molecular weight of about 22 kDa, made up of 191 amino acid residues, and two disulfide links. FGH binds to particular growth hormone receptors (GHR) in fish to exert its functional activity, which is determined by its structural characteristics. GHR is widely distributed in organs such the liver, muscle, bone, and skin and is a member of the type I cytokine receptor family. A number of intracellular signaling cascades, most notably the JAK2/STAT and MAPK/ERK pathways, are activated when FGH binds to GHR.

The receptor-associated tyrosine kinase JAK2 is activated in the JAK2/STAT pathway when FGH binds to the GHR and causes receptor dimerization. JAK2 activation causes particular tyrosine sites on the intracellular portion of the receptor to become phosphorylated, which in turn attracts and activates STAT (Signal Transducer and Activator of Transcription). In order to promote the transcription and expression of target genes and control genes linked to growth and metabolism, the activated STAT enters the nucleus and binds to particular DNA sequences. Furthermore, FGH also activates the MAPK/ERK pathway, which involves signaling molecules like ERK, MEK, Raf, and Ras. This pathway's activation promotes cell division and proliferation, which is especially crucial for tissues like muscles and bones. The regulating role of FGH in fish growth and development is seen in several ways. First, by boosting protein synthesis, preventing protein breakdown, and promoting muscle cell division and proliferation, FGH stimulates muscular growth. By encouraging chondrocyte differentiation and proliferation as well as osteoblast activation, FGH promotes bone growth and development in the skeletal system. Additionally, FGH encourages the breakdown and utilization of fats, which decreases the body's accumulation of fat and increases the availability of protein and energy. This is very crucial in aquaculture to increase the production of lean meat. To guarantee that fish have an adequate source of energy, FGH also regulates metabolism by improving the absorption of amino acids and glucose. Seasonal variations, environmental influences, and nutritional status are some of the variables that affect the secretion and control of FGH. FGH secretion is greatly influenced by nutrition; consuming enough protein and energy can increase FGH secretion and foster growth. Temperature variations and other environmental factors have a big impact on FGH secretion levels. Generally speaking, FGH secretion rises at the right temperature, which accelerates fish growth. Moreover, FGH secretion is somewhat regulated by sexual maturity and circadian rhythms.

Overview of cAMP/PKA/CREB Pathway in GH Regulation (Vélez EJ, 2021) Figure 1. Simplified Overview of the cAMP/PKA/CREB Pathway Regulating GH Synthesis and Secretion (Source: Vélez EJ, Unniappan S. 2021)

The use of FGH in aquaculture has significant financial advantages. The growth rate of farmed fish can be directly increased by injecting exogenous FGH or its analogs, which will reduce the farming cycle and increase yields. Genetic engineering methods have been progressively used in FGH research in recent years. For example, transgenic technology has been used to introduce the FGH gene into fish, enabling steady high-level production of FGH during growth, which has been demonstrated to efficiently boost growth. However, the application of FGH must also take into account possible ecological concerns and food safety issues, particularly when it comes to the widespread usage of FGH or its analogs, which may have an effect on aquatic ecosystems. As a result, maximizing the use of FGH in aquaculture to accomplish productive farming while maintaining ecological balance and food safety has emerged as a key area of study. To sum up, Fish Growth Hormone (FGH) is essential for controlling fish growth because it binds to growth hormone receptors and triggers signaling pathways such MAPK/ERK and JAK2/STAT, which control the expression of genes linked to growth and metabolism. FGH has a wide range of potential uses as an efficient way to support aquaculture expansion. Studies on the molecular makeup, mode of action, and application techniques of FGH will continue to grow as biotechnology continues to progress, giving the aquaculture sector fresh momentum.

Alternative Names

Fish GH ELISA kit
Fish growth hormone detection kit
Growth hormone ELISA for fish

References

1. Vélez EJ, Unniappan S. A Comparative Update on the Neuroendocrine Regulation of Growth Hormone in Vertebrates. Front Endocrinol. 2021;11:614981.

Documents

pdf COA

pdf SDS

pdf Datasheet

QA & Reviews

Customer Reviews

References

Congenital growth hormone deficiency associated with hip dysplasia and Legg-Calve-Perthes disease

CLINICAL ENDOCRINOLOGY

Authors: Lamback, Elisa B.; Chiarini, Stella; Roposch, Andreas; Dattani, Mehul T.

Abstract

Objective Growth hormone deficiency (GHD) is usually treated with recombinant human GH (rhGH), and this has been rarely associated with hip disorders. We analysed the clinical data of patients with congenital GHD receiving rhGH who had associated hip dysplasia or Legg-Calve-Perthes disease (LCPD), with a view to determining whether the hip dysplasia was associated with the underlying disease or with rhGH treatment. Design We performed a retrospective analysis of paediatric and adolescent patients seen between 1992-2018 with congenital GHD and hip disorders. Data were collected through a review of the patients' medical records and included demographics, clinical and imaging data, and the time frame between the onset of the symptoms related to the hip disorders and the onset of GH treatment. Results Of the 13 patients with hip disorders, hip dysplasia was present in ten patients and LCPD in three. Hip dysplasia was diagnosed before rhGH was initiated in 50% of cases. These patients had bilateral hip dysplasia and isolated GHD. LCPD was diagnosed in one patient before rhGH was commenced and did not progress. In two patients, LCPD was diagnosed after rhGH was started and did temporarily progress in one of them, but rhGH was not discontinued because LCPD did not seem to be related to rhGH treatment. Conclusions This study suggests that hip dysplasia could be a manifestation of an underlying GHD. Additionally, rhGH treatment may not necessarily be causative of LCPD.

Obesity can offset the cardiometabolic benefits of gestational exercise

INTERNATIONAL JOURNAL OF OBESITY

Authors: Perales, Maria; Valenzuela, Pedro L.; Barakat, Ruben; Alejo, Lidia B.; Cordero, Yaiza; Pelaez, Mireia; Lucia, Alejandro

Abstract

Pregnancy exercise can prevent excessive gestational weight gain (EGWG), gestational diabetes mellitus (GDM) and hypertension (GH), but inter-individual variability has not been explored. We aimed to analyze the prevalence--and potential sociodemographic and medical predictors of--non-responsiveness to gestational exercise, and the association of non-responsiveness with adverse pregnancy outcomes. Among 688 women who completed a supervised light-to-moderate intensity exercise program (three similar to 1-h sessions/week including aerobic, resistance, and pelvic floor muscle training) until near-term, those who showed EGWG, GDM or GH were considered 'non-responders'. A low prevalence of non-responders was observed for GDM (3.6%) and GH (3.4%), but not for EGWG (24.2%). Pre-pregnancy obesity was the strongest predictor of non-responsiveness for GH (odds ratio 8.40 [95% confidence interval 3.10-22.78] and EGWG (5.37 [2.78-10.39]), whereas having a highest education level attenuated the risk of being non-responder for GDM (0.10 [0.02-0.49]). Non-responsiveness for EGWG was associated with a higher risk of prolonged labor length, instrumental/cesarean delivery, and macrosomia, and of lower Apgar scores. No association with negative delivery outcomes was found for GDM/GH. In summary, women with pre-pregnancy obesity might require from additional interventions beyond light-to-moderate intensity gestational exercise (e.g., diet and/or higher exercise loads) to ensure cardiometabolic benefits.